Caricamento...
Antiangiogenic therapy in breast cancer
Based on a strong rationale for anti-VEGF (vascular endothelial growth factor) treatment in breast cancer and promising preclinical data, great hopes have been placed on the anti-VEGF antibody bevacizumab. Clinical trials, however, reported conflicting results. In metastatic human epidermal growth f...
Salvato in:
| Pubblicato in: | Memo |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Vienna
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5725520/ https://ncbi.nlm.nih.gov/pubmed/29250196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-017-0362-0 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|